Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. - Wikidata - awgldk - TriplyDB

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

http://www.wikidata.org/entity/Q33620083

about

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Targeted Therapy in Biliary Tract Cancers Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Optimum chemotherapy for the management of advanced biliary tract cancer Progression of targeted therapy in advanced cholangiocarcinoma Management of perihilar cholangiocarcinoma in the era of multimodal therapy Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures Targeted therapy in biliary tract cancers-current limitations and potentials in the future.Targeting Angiogenesis in Biliary Tract Cancers: An Open Option Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials.The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation.Recent advances in the regulation of cholangiocarcinoma growth Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors Update on the management of cholangiocarcinoma.Systemic Therapy of Cholangiocarcinoma.EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma Targeting metastatic upper gastrointestinal adenocarcinomas Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.Molecular genetics and targeted therapeutics in biliary tract carcinoma.Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Targeted therapy for biliary tract cancer.Current status of chemotherapy for the treatment of advanced biliary tract cancer.Current therapy and future directions in biliary tract malignancies.EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma.AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.

P2860

Q26751224-494B3F64-C63B-45CE-94DE-66FAE443A3E3 Q26798443-32DDD1B4-84B7-4FC0-BD23-818CDF952390 Q26852049-25172854-C894-400A-94C8-83DFF9B43A2C Q27002547-285559ED-525A-48AC-B43F-73791503BFA1 Q27010873-10F2B2D1-275C-44FE-ADF4-50B77248192E Q27016150-B8DCBB2A-1031-4F4B-B509-8C6253C2BE75 Q28273788-B252001C-2012-400B-A809-5DBF9C52D2A8 Q28550991-97711FFE-9F97-4E8F-B679-2CDA7C1D54FE Q30234532-6C571A8A-D0E4-40DD-9832-24F07C6D0516 Q30398807-0BC52C1D-1C24-4DEC-8EBB-1BD071EDC0FC Q33395417-6DBE4C8E-ADA2-4CEA-8A15-239DBAF75188 Q33408279-BDC95D07-76FB-4EA1-8CB3-B6CB36B0B727 Q33440859-AD69712A-29F3-4C01-A1C1-BA252B303BA7 Q33441341-6D691A28-F1D5-40CD-BAD8-92C764AFA706 Q33686690-B6BFA876-597C-4F67-9740-BFF7D51A1E67 Q33775133-1BB4A61D-2163-4B05-900E-A022D110B39D Q33994814-4AEE2BE6-4F55-41EC-A3F2-E8DA65CB589A Q34104493-F94D1ED0-5B5D-427A-BC51-10FB8F02DF12 Q34153255-940CDDD2-1D83-47AA-BB4E-337BECEAD584 Q34551877-85BAB8BC-6563-424D-BECE-CAADD7C30529 Q34738001-07DA8DFE-AFBC-4D53-8C4E-5CA0E9C1C9F4 Q35000785-075471F9-69A8-4C05-B7BE-3DFBD0EC95AC Q35640101-0CE78378-D0E7-455C-85A5-FB83E3C10B66 Q35674607-5DFA37CD-8211-4C25-BF69-DFBD76561921 Q35820533-79FC6EB8-1536-4B89-A237-DEC971680740 Q36270115-EE68C08D-B2E4-4ECE-9F0B-69E4D67951F1 Q36287599-2ADF7E2D-9DF1-42A2-B612-00CA9AE59D40 Q36376264-0F3424E1-7B89-46EC-9640-892B98507030 Q36488070-0EE29573-7468-4DAD-A92B-ABB7C6890C3D Q36759538-1AB5F6E6-566F-481E-BD95-4C3D238A6B0F Q36822722-93D36674-A5D6-408A-BA17-2C4F36FF1E18 Q36962011-C5936254-7A19-4AC4-BF57-FC67A7FF3CA6 Q37017110-DACE752A-A94A-481C-93F6-B17B43BC1EB7 Q37132750-8B0E9DB7-E3C4-449E-AA21-46EA5717C283 Q37138732-D29E50A7-416D-466A-8AD1-5FF512B73CFD Q37161293-053AACF8-81D0-4175-801C-017068844E07 Q37215717-8FC01B20-9530-4C7B-920E-97F7778BADBA Q37225342-5E01897C-6D1A-4362-8FA6-8BCE9CD60703 Q37719383-39EE428B-4B1B-4B79-9310-6FFFDC15F8B7 Q37725603-8342B142-01C0-49B8-A944-1F359CC36E78

P2860

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

http://www.wikidata.org/entity/Q33620083

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

@ast

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

@en

type

label

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

@ast

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

@en

prefLabel

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

@ast

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

@en

P1433

Q33620083-AF0A3E24-428D-441F-B127-AA3980B1697E

P1476

Q33620083-AA80D5AA-21F2-42FA-839D-3FB59EDC301E

P2093

Q33620083-261CAC64-1BAA-44DE-88C5-53AE43692D88

Q33620083-2D30E2E0-356A-440B-9B92-7AC77D6CDFC8

Q33620083-2D5A8370-0260-4356-A11E-FA1FE88F25A3

Q33620083-2F972E1A-D669-4106-9FA9-022D6A3E75EC

Q33620083-3A835888-57D0-4850-A8A3-F11A28217D55

Q33620083-401D0B4C-22F3-4B57-9309-E5AEA688BD9E

Q33620083-42A3B67E-8BBF-4D6C-9339-14CCB0FD1F5B

Q33620083-8F2393C0-5E2C-4F65-AD8F-598544B31F4A

Q33620083-9F436234-1B48-4FA0-8ACF-A413FA6BBDFD

Q33620083-A3200AF3-453F-4111-AD2B-19F948D21F1A

P2860

Q33620083-0DDE095B-DA90-4BE7-99F6-DD599F5730B2

Q33620083-0F03BF9B-EBB2-41E8-AF1D-DDD1FE77DF35

Q33620083-1D2A28EA-9A95-4AAC-8911-CD390309BC5F

Q33620083-378E5A7C-F70F-4382-AD34-8C48F4CC715D

Q33620083-3F48FE9D-97D1-4239-8EB1-2F3EEAF5F80C

Q33620083-451122E4-CE5D-4C43-8C6F-8CBDD3289969

Q33620083-4D33114E-9E6D-4C41-B7B1-A53DE43246A3

Q33620083-62F51F2D-63CB-4E39-AD13-DEDCE624D034

Q33620083-6CBC3CA9-AF96-41C4-BC70-BC1C6A05A24C

Q33620083-6EEE7FB9-AA2E-4A9D-880E-C2B7D6BB64C2

P2888

Q33620083-5D702DC0-185D-416A-954B-03EA582E467C

P304

Q33620083-56AF7A4E-3FAC-4BE0-9305-00EB8C313029

P31

Q33620083-6178F097-1E74-48FA-8532-2CBC0A6811EB

P356

Q33620083-82068996-2878-453B-99AD-86527F58917D

P407

Q33620083-B9072422-8C20-4417-838F-165EFBEBB97C

P433

Q33620083-DF053E07-7FF2-41AA-B676-042BDE927553

P478

Q33620083-4A7BD004-D925-4822-85E5-C0C495EAA820

P577

Q33620083-9162323B-6F2D-4431-88EB-AB3CDF25B88B

P5875

Q33620083-8A5E3EA0-313F-4CC9-A7D8-656D30B50457

P6179

Q33620083-5BF6B699-9B99-4A1A-AC98-6EDA64276F54

P698

Q33620083-58DFFE2F-3D97-44B4-A6F1-1FCF6E8745C2

P921

Q33620083-C7821727-3B56-4F69-A9DB-37B591737127

P932

Q33620083-7F9F79B1-A74D-4994-A5FB-F32B3C394922

P356

P1433

British Journal of Cancer

P1476

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

@en

P2093

A Fontana

http://www.w3.org/2001/XMLSchema#string

C Bengala

http://www.w3.org/2001/XMLSchema#string

C Boni

http://www.w3.org/2001/XMLSchema#string

C Dealis

http://www.w3.org/2001/XMLSchema#string

C Del Giovane

http://www.w3.org/2001/XMLSchema#string

E Aitini

http://www.w3.org/2001/XMLSchema#string

F Bertolini

http://www.w3.org/2001/XMLSchema#string

G Luppi

http://www.w3.org/2001/XMLSchema#string

N Malavasi

http://www.w3.org/2001/XMLSchema#string

P Conte

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.

Biliary tract cancers.

Outcome of treatment for distal bile duct cancer.

Epidemiology and molecular pathology of gallbladder cancer.

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

Raf: a strategic target for therapeutic development against cancer.

P2888

P304

68-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605458

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40029097

http://www.w3.org/2001/XMLSchema#string

P6179

1037551138

http://www.w3.org/2001/XMLSchema#string

P698

19935794

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2813746

http://www.w3.org/2001/XMLSchema#string